Sebastien A. Anguille

Antwerpen, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 83 publications

Inflammatory mechanisms in the AML bone marrow niche: From pathogenesis to therapy.

Inflammatory mechanisms in the AML bone marrow niche: From pathogenesis to therapy.

Journal: Cytokine & growth factor reviews

Published: July 09, 2026

Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy.

Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy.

Journal: Technology in cancer research & treatment

Published: June 29, 2026

Endotheliopathy in CAR T-Cell Therapy: Mechanistic Insights into the VWF/ADAMTS13 Axis and the Angiopoietin-Tie2 Pathway.

Endotheliopathy in CAR T-Cell Therapy: Mechanistic Insights into the VWF/ADAMTS13 Axis and the Angiopoietin-Tie2 Pathway.

Journal: TH open : companion journal to thrombosis and haemostasis

Published: May 08, 2026

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.

Journal: The Lancet. Haematology

Published: March 02, 2026

The search for safe and effective CAR-T targets in AML.

The search for safe and effective CAR-T targets in AML.

Journal: Blood cancer journal

Published: March 01, 2026

RNA-based co-transfer of human CD8αβ with WT1-specific TCRαβ redirects tumor recognition by CD4 and γδ T-cells towards MHC class I-restricted WT1 epitopes and boosts CD8 T-cell responses with or without CD3 mRNA.

RNA-based co-transfer of human CD8αβ with WT1-specific TCRαβ redirects tumor recognition by CD4 and γδ T-cells towards MHC class I-restricted WT1 epitopes and boosts CD8 T-cell responses with or without CD3 mRNA.

Journal: Experimental hematology & oncology

Published: December 18, 2025

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Journal: Advances in therapy

Published: September 02, 2025

Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.

Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.

Journal: Leukemia

Published: June 23, 2025

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.

Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.

Journal: Blood advances

Published: May 06, 2025

Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.

Correction: WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.

Journal: Journal of hematology & oncology

Published: March 20, 2025

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.

Journal: European journal of haematology

Published: March 12, 2025

Expanding the CAR toolbox with high throughput screening strategies for CAR domain exploration: a comprehensive review.

Expanding the CAR toolbox with high throughput screening strategies for CAR domain exploration: a comprehensive review.

Journal: Journal for immunotherapy of cancer

Published: March 06, 2025

Showing 1-12 of 83

Last Updated: 09/26/2026